株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

肥満症:パイプライン製品の分析

Obesity - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 232860
出版日 ページ情報 英文 494 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.77円で換算しております。
Back to Top
肥満症:パイプライン製品の分析 Obesity - Pipeline Review, H1 2017
出版日: 2017年05月23日 ページ情報: 英文 494 Pages
概要

肥満症は、身体に過度の脂肪を蓄積した状態をいい、心臓病や糖尿病、高血圧などの疾患のリスクを高めます。素因には、年齢、家族歴、禁煙、睡眠不足、一部の投薬などがあり、健康的な生活、投薬、手術などの治療法があります。

当レポートでは、世界における肥満症治療薬のパイプラインについて取り上げ、現在の開発パイプラインの状況や最新動向、薬剤プロファイル、主要企業および開発中の製品レビューなどをお届けいたします。

イントロダクション

肥満症の概要

治療薬の開発

治療薬の評価

治療薬開発に従事している企業

薬剤プロファイル

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9362IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Obesity - Pipeline Review, H1 2017, provides an overview of the Obesity (Metabolic Disorders) pipeline landscape.

Obesity is defined as having an excessive amount of body fat. Obesity increases risk of diseases and health problems such as heart disease, diabetes and high blood pressure. The predisposing factors include age, family history, quitting smoking, lack of sleep and certain medications. Treatment includes healthy lifestyle, medications and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Obesity - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Obesity (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Obesity (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Obesity and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 3, 16, 22, 129, 30 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 50 and 14 molecules, respectively.

Obesity (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Obesity (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Obesity (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Obesity (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Obesity (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Obesity (Metabolic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Obesity (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Obesity (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Obesity - Overview
  • Obesity - Therapeutics Development
  • Obesity - Therapeutics Assessment
  • Obesity - Companies Involved in Therapeutics Development
  • Obesity - Drug Profiles
  • Obesity - Dormant Projects
  • Obesity - Discontinued Products
  • Obesity - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Obesity, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..7), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..8), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..9), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..10), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Obesity - Pipeline by Abeome Corp, H1 2017
  • Obesity - Pipeline by Adamas Pharmaceuticals Inc, H1 2017
  • Obesity - Pipeline by Advinus Therapeutics Ltd, H1 2017
  • Obesity - Pipeline by Aegis Therapeutics LLC, H1 2017
  • Obesity - Pipeline by Akron Molecules AG, H1 2017
  • Obesity - Pipeline by Alize Pharma SAS, H1 2017
  • Obesity - Pipeline by Amabiotics SAS, H1 2017
  • Obesity - Pipeline by Amgen Inc, H1 2017
  • Obesity - Pipeline by Aoxing Pharmaceutical Company Inc, H1 2017
  • Obesity - Pipeline by Arrowhead Pharmaceuticals Inc, H1 2017
  • Obesity - Pipeline by AstraZeneca Plc, H1 2017
  • Obesity - Pipeline by Asubio Pharma Co Ltd, H1 2017
  • Obesity - Pipeline by Athersys Inc, H1 2017
  • Obesity - Pipeline by Biophytis SAS, H1 2017
  • Obesity - Pipeline by BioRestorative Therapies Inc, H1 2017
  • Obesity - Pipeline by Biozeus, H1 2017
  • Obesity - Pipeline by Boehringer Ingelheim GmbH, H1 2017
  • Obesity - Pipeline by Braasch Biotech LLC, H1 2017
  • Obesity - Pipeline by C3J Therapeutics Inc, H1 2017
  • Obesity - Pipeline by Camurus AB, H1 2017
  • Obesity - Pipeline by Carmot Therapeutics Inc, H1 2017
  • Obesity - Pipeline by CohBar Inc, H1 2017
  • Obesity - Pipeline by CoMentis Inc, H1 2017
  • Obesity - Pipeline by Connexios Life Sciences Pvt Ltd, H1 2017
  • Obesity - Pipeline by ConSynance Therapeutics Inc, H1 2017
  • Obesity - Pipeline by Corium International Inc, H1 2017
  • Obesity - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
  • Obesity - Pipeline by DiscoveryBiomed Inc, H1 2017
  • Obesity - Pipeline by Eisai Co Ltd, H1 2017
  • Obesity - Pipeline by Eli Lilly and Company, H1 2017
  • Obesity - Pipeline by Esperion Therapeutics Inc, H1 2017
  • Obesity - Pipeline by Eternygen GmbH, H1 2017
  • Obesity - Pipeline by Evotec AG, H1 2017
  • Obesity - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Obesity - Pipeline by FibroGen Inc, H1 2017
  • Obesity - Pipeline by Genmedica Therapeutics SL, H1 2017
  • Obesity - Pipeline by Gila Therapeutics Inc, H1 2017
  • Obesity - Pipeline by Gilead Sciences Inc, H1 2017
  • Obesity - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Obesity - Pipeline by Glucox Biotech AB, H1 2017
  • Obesity - Pipeline by GTx Inc, H1 2017
  • Obesity - Pipeline by HanAll Biopharma Co Ltd, H1 2017
  • Obesity - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
  • Obesity - Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2017
  • Obesity - Pipeline by Immungenetics AG, H1 2017
  • Obesity - Pipeline by Intarcia Therapeutics Inc, H1 2017
  • Obesity - Pipeline by Ionis Pharmaceuticals Inc, H1 2017
  • Obesity - Pipeline by Ixchel Pharma LLC, H1 2017
  • Obesity - Pipeline by Jenrin Discovery Inc, H1 2017
  • Obesity - Pipeline by Johnson & Johnson, H1 2017
  • Obesity - Pipeline by Laboratorios Silanes SA de CV, H1 2017
  • Obesity - Pipeline by Lead Discovery Center GmbH, H1 2017
  • Obesity - Pipeline by Leading BioSciences Inc, H1 2017
  • Obesity - Pipeline by Lotus Pharmaceutical Co Ltd, H1 2017
  • Obesity - Pipeline by M Pharmaceutical Inc, H1 2017
  • Obesity - Pipeline by Magnus Life Ltd, H1 2017
  • Obesity - Pipeline by MedImmune LLC, H1 2017
  • Obesity - Pipeline by Merck & Co Inc, H1 2017
  • Obesity - Pipeline by Mitochon Pharmaceuticals Inc, H1 2017
  • Obesity - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017
  • Obesity - Pipeline by NeuroNano Pharma Inc, H1 2017
  • Obesity - Pipeline by NGM Biopharmaceuticals Inc, H1 2017
  • Obesity - Pipeline by NIBEC, H1 2017
  • Obesity - Pipeline by Nordic Bioscience A/S, H1 2017
  • Obesity - Pipeline by Novartis AG, H1 2017
  • Obesity - Pipeline by Novo Nordisk A/S, H1 2017
  • Obesity - Pipeline by ObeTherapy Biotechnology, H1 2017
  • Obesity - Pipeline by Omeros Corp, H1 2017
  • Obesity - Pipeline by OPKO Biologics Ltd, H1 2017
  • Obesity - Pipeline by OPKO Health Inc, H1 2017
  • Obesity - Pipeline by Pfizer Inc, H1 2017
  • Obesity - Pipeline by PharmaIN Corp, H1 2017
  • Obesity - Pipeline by Poxel SA, H1 2017
  • Obesity - Pipeline by Progenra Inc, H1 2017
  • Obesity - Pipeline by Prometheon Pharma LLC, H1 2017
  • Obesity - Pipeline by ReCyte Therapeutics Inc, H1 2017
  • Obesity - Pipeline by Renova Therapeutics Inc, H1 2017
  • Obesity - Pipeline by Reviva Pharmaceuticals Inc, H1 2017
  • Obesity - Pipeline by Saniona AB, H1 2017
  • Obesity - Pipeline by Sanofi, H1 2017
  • Obesity - Pipeline by Seoul Pharma Co Ltd, H1 2017
  • Obesity - Pipeline by Shionogi & Co Ltd, H1 2017
  • Obesity - Pipeline by Sinil Pharmaceutical Co Ltd, H1 2017
  • Obesity - Pipeline by Sorrento Therapeutics Inc, H1 2017
  • Obesity - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017
  • Obesity - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
  • Obesity - Pipeline by Toray Industries Inc, H1 2017
  • Obesity - Pipeline by Umecrine AB, H1 2017
  • Obesity - Pipeline by Vicore Pharma AB, H1 2017
  • Obesity - Pipeline by Viking Therapeutics Inc, H1 2017
  • Obesity - Pipeline by WhanIn Pharmaceutical Co Ltd, H1 2017
  • Obesity - Pipeline by Xenetic Biosciences Inc, H1 2017
  • Obesity - Pipeline by XL-protein GmbH, H1 2017
  • Obesity - Pipeline by Yuyu Pharma Inc, H1 2017
  • Obesity - Pipeline by Zafgen Inc, H1 2017
  • Obesity - Pipeline by Zealand Pharma AS, H1 2017
  • Obesity - Dormant Projects, H1 2017
  • Obesity - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Obesity - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Obesity - Dormant Projects, H1 2017 (Contd..3), H1 2017
  • Obesity - Dormant Projects, H1 2017 (Contd..4), H1 2017
  • Obesity - Dormant Projects, H1 2017 (Contd..5), H1 2017
  • Obesity - Dormant Projects, H1 2017 (Contd..6), H1 2017
  • Obesity - Dormant Projects, H1 2017 (Contd..7), H1 2017
  • Obesity - Dormant Projects, H1 2017 (Contd..8), H1 2017
  • Obesity - Dormant Projects, H1 2017 (Contd..9), H1 2017
  • Obesity - Dormant Projects, H1 2017 (Contd..10), H1 2017
  • Obesity - Dormant Projects, H1 2017 (Contd..11), H1 2017
  • Obesity - Dormant Projects, H1 2017 (Contd..12), H1 2017
  • Obesity - Dormant Projects, H1 2017 (Contd..13), H1 2017
  • Obesity - Discontinued Products, H1 2017
  • Obesity - Discontinued Products, H1 2017 (Contd..1), H1 2017
  • Obesity - Discontinued Products, H1 2017 (Contd..2), H1 2017
  • Obesity - Discontinued Products, H1 2017 (Contd..3), H1 2017

List of Figures

  • Number of Products under Development for Obesity, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top